EUVIMEDEUVIMED entdecken
Crossref

Accelerated Partial Breast Irradiation (APBI) For Ductal Carcinoma In Situ

Diana Roth O'Brien, Lillian Boe, Andrea Barrio, Boris Mueller, J Isabelle Choi, John Cuaron, Beryl McCormick, Atif J Khan, Simon N Powell, Lior Z Braunstein

Clinical Breast Cancer · 2025

DOI: 10.1016/j.clbc.2025.10.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2025. Verfasst von Diana Roth O'Brien und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Neoplasm Recurrence, Local, Brachytherapy. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Institutes of Health, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE/OBJECTIVES: Suitability criteria for partial breast irradiation (PBI) are narrowly constrained for those with ductal carcinoma in situ (DCIS). In comparison to invasive disease, guidance is limited regarding the optimal application of PBI to treat DCIS. Here, we report disease outcomes for a heterogeneous cohort of patients with DCIS who received PBI. MATERIALS/METHODS: Using a prospectively maintained institutional database, we identified patients with DCIS who underwent lumpectomy and adjuvant PBI from 2008 to 2022. Based on clinicopathologic characteristics patients were classified as suitable, cautionary, or unsuitable for PBI by American Society for Radiation Oncology (ASTRO) criteria. The primary endpoint was local recurrence (LR). RESULTS: The cohort comprised 176 patients with DCIS who received PBI, median age 60 years (interquartile range (IQR) 52, 66). Median DCIS size was 9 mm (IQR 4, 15 mm), and approximately 20% had multifocal disease. Most patients had negative (≥ 2 mm) final surgical margins (n = 160, 91%), 10 had < 2 mm margins and 6 had ≤ 1 mm margins for DCIS. 18 (10%) patients had nuclear grade 1 disease, 111 (63%) had grade 2 disease, and 33 (19%) had grade 3 disease, with a small subset classified as grade 1-2 or 2-3. Most patients (n = 161, 91%) had estrogen receptor (ER) positive DCIS, and 72 (41%) received endocrine therapy. By ASTRO criteria, 118 (67%) patients were suitable for PBI, 57 (32%) were considered cautionary, and 1 (0.6%) was unsuitable. At a median 24 months of follow up (range 2-127 months) we observed a single LR, yielding a 2-year LR rate of 0.6%. The LR occurred in a patient classified as cautionary, yielding a 2-year LR rate of 1.8% for the cautionary subset. No breast cancer mortality events were observed. CONCLUSIONS: These early-term results exhibit excellent local control for patients with DCIS who received lumpectomy and PBI, even among those classified as "cautionary" by national guidelines. Although our findings are limited by short follow up, these results suggest that broadening the application of PBI for patients with DCIS may warrant further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCarcinoma, Intraductal, NoninfiltratingNeoplasm Recurrence, LocalBrachytherapyHumansFemaleMiddle AgedMastectomy, SegmentalAgedRadiotherapy, AdjuvantMargins of ExcisionFollow-Up StudiesRetrospective StudiesProspective Studies

Stichwörter der Autor:innen

APBIBreast cancerBreast conservationDCISPartial breast irradiationRadiotherapy

Autor:innen und Institutionen

  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: BRAUNSTL@mskcc.org.

Förderung

  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

O'Brien, D. R., Boe, L., Barrio, A., Mueller, B., Choi, J. I., Cuaron, J., McCormick, B., Khan, A. J., Powell, S. N., & Braunstein, L. Z. (2025). Accelerated Partial Breast Irradiation (APBI) For Ductal Carcinoma In Situ. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.10.001

Vancouver

O'Brien DR, Boe L, Barrio A, Mueller B, Choi JI, Cuaron J, et al. Accelerated Partial Breast Irradiation (APBI) For Ductal Carcinoma In Situ. Clinical Breast Cancer. 2025. doi:10.1016/j.clbc.2025.10.001

BibTeX
@article{OBrien2025,
  author = {O'Brien, Diana Roth and Boe, Lillian and Barrio, Andrea and Mueller, Boris and Choi, J Isabelle and Cuaron, John and McCormick, Beryl and Khan, Atif J and Powell, Simon N and Braunstein, Lior Z},
  title = {Accelerated Partial Breast Irradiation (APBI) For Ductal Carcinoma In Situ},
  journal = {Clinical Breast Cancer},
  year = {2025},
  doi = {10.1016/j.clbc.2025.10.001}
}
Kostenlos starten →